Philips intends to extend maturity of forward purchases of 4 million shares for long-term incentive plans
Philips (NYSE: PHG) has announced its intention to extend the settlement of two forward contracts related to its long-term incentive plans share program. The extension involves 4 million shares (2 million shares each) and will push the original maturity dates from Q4 2025 to Q4 2026.
These forward contracts are part of the company's share repurchase program that was previously announced on June 14, 2023.
Questi contratti forward fanno parte del programma di riacquisto azioni dell'azienda, annunciato in precedenza il 14 giugno 2023.
Estos contratos forward forman parte del programa de recompra de acciones de la empresa que se anunció previamente el 14 de junio de 2023.
이 선도계약은 회사의 주식 매입 프로그램의 일부로, 2023년 6월 14일에 이미 발표되었습니다.
Ces contrats à terme font partie du programme de rachat d'actions de l'entreprise qui a été annoncé précédemment le 14 juin 2023.
Diese Forward-Verträge sind Teil des bereits am 14. Juni 2023 angekündigten Aktienrückkaufprogramms des Unternehmens.
هذه العقود الآجلة جزء من برنامج إعادة شراء الأسهم للشركة الذي أُعلن عنه سابقاً في 14 يونيو 2023.
这些远期合同是公司此前于 2023 年 6 月 14 日宣布的股票回购计划的一部分。
- None.
- None.
September 15, 2025
Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA) announces today that it intends to extend the settlement of two forward contracts for 2 million long-term incentive plans shares each as part of the share repurchase program earlier announced on June 14, 2023. The planned extension will postpone the original maturity dates in Q4 2025 by one year to a new maturity date in Q4 2026. Further details will be available via this link.
For further information, please contact:
Michael Fuchs
Philips Global External Relations
Tel.: +31 6 1486 9261
E-mail: michael.fuchs@philips.com
Dorin Danu
Philips Investor Relations
Tel.: +31 20 59 77055
E-mail: dorin.danu@philips.com
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people’s health and well-being through meaningful innovation. Philips’ patient- and people-centric innovation leverages advanced technology and deep clinical and consumer insights to deliver personal health solutions for consumers and professional health solutions for healthcare providers and their patients in the hospital and the home.
Headquartered in the Netherlands, the company is a leader in diagnostic imaging, ultrasound, image-guided therapy, monitoring and enterprise informatics, as well as in personal health. Philips generated 2024 sales of EUR 18 billion and employs approximately 67,300 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
Forward-looking statements
This release contains certain forward-looking statements with respect to the financial condition, results of operations and business of Philips and certain of the plans and objectives of Philips with respect to these items. Examples of forward-looking statements include statements made about the strategy, estimates of sales growth, future EBITA, future developments in Philips’ organic business and the completion of acquisitions and divestments. By their nature, these statements involve risk and uncertainty because they relate to future events and circumstances and there are many factors that could cause actual results and developments to differ materially from those expressed or implied by these statements.
FAQ
What is the purpose of Philips' forward contract extension announcement?
How many shares are affected by Philips' forward contract extension?
When will Philips' forward contracts reach their new maturity date?
When was Philips' share repurchase program initially announced?
